Calcium voltage-gated channel subunit alpha1 S
Certain CACNA1S variants confer susceptibility to malignant hyperthermia, a serious reaction to triggering anesthetics. The Gene2Rx assessment concerns a defined set of variants and is available only for eligible original WGS data.[1]
Gene2Rx uses definitions covering 2 named CACNA1S alleles, built from 2 variants in CPIC targeted screen. WGS only; no listed variant detected does not rule out susceptibility.
CACNA1S alleles are named by the underlying DNA variant rather than a star number. For example, c.61C>T describes a single base change at position 61 of the coding sequence.
DNA variant labels identify sequence differences. Their interpretation depends on the particular gene, the evidence, and the variants that can be assessed in your data. A DNA result does not directly measure enzyme activity.
The source of these definitions is listed above. Missing variants or incomplete coverage can leave a result indeterminate.
This list contains 7 medications with CACNA1S information from the sources shown below. Evidence and report eligibility differ by drug; each page explains its scope and limitations.
These branded medications include at least one active ingredient whose metabolism or action involves CACNA1S. Each links to its full pharmacogenetic breakdown.
A Gene2Rx report interprets supported variants in the context of your data and purchased report. Missing or uncertain calls may prevent an assessment.
Get your report Look up a medicationInformational only, not medical advice. The presence of a CACNA1S pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.